| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2159399 | Radiotherapy and Oncology | 2010 | 4 Pages |
Abstract
This paper reports on an evaluation of 5 RapidArc® optimization approaches vs IMRT. This study includes 11 patients with adenocarcinoma of the prostate. Rectal Normal Tissue Complication Probability is used as a constraint in a dose escalation. RapidArc® rectal NTCP’s are lower than those of IMRT (p = 0.007). This allows a mean dose escalation of 2.1 Gy([0.7 Gy,3.5 Gy]).
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Wouter Crijns, Tom Budiharto, Gilles Defraene, Jan Verstraete, Tom Depuydt, Karin Haustermans, Frank Van den Heuvel,